Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Restructuring Costs (2020 - 2024)

Bioventus (BVS) has disclosed Restructuring Costs for 5 consecutive years, with -$52000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Restructuring Costs rose 26.76% year-over-year to -$52000.0, compared with a TTM value of -$52000.0 through Dec 2024, down 106.19%, and an annual FY2025 reading of $2.2 million, up 4398.08% over the prior year.
  • Restructuring Costs was -$52000.0 for Q4 2024 at Bioventus, up from -$71000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $4.6 million in Q4 2022 and bottomed at -$71000.0 in Q4 2023.
  • Average Restructuring Costs over 5 years is $884750.0, with a median of $576000.0 recorded in 2022.
  • The sharpest move saw Restructuring Costs soared 570.54% in 2022, then tumbled 104.52% in 2023.
  • Year by year, Restructuring Costs stood at $563000.0 in 2020, then increased by 22.38% to $689000.0 in 2021, then skyrocketed by 570.54% to $4.6 million in 2022, then plummeted by 101.54% to -$71000.0 in 2023, then rose by 26.76% to -$52000.0 in 2024.
  • Business Quant data shows Restructuring Costs for BVS at -$52000.0 in Q4 2024, -$71000.0 in Q4 2023, and -$26000.0 in Q3 2023.